Inhibiting IL-1B, however, may or may not be helpful for patients based on its polymorphism, depending on the cancer kind or stage, the primary type of immune cells present in the tumor microenvironment, and the anti-cancer treatment utilized [45]. Here, IL1B is linked to neoplasm.